TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases $33,900.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young bought 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were purchased at an average cost of $5.65 per share, with a total value of $33,900.00. Following the transaction, the chief financial officer now directly owns 30,000 shares of the company’s stock, valued at $169,500. The trade was a 25.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

James Emmett Young also recently made the following trade(s):

• On Monday, January 27th, James Emmett Young bought 24,000 shares of TriSalus Life Sciences stock. The shares were purchased at an average cost of $5.40 per share, with a total value of $129,600.00.

TriSalus Life Sciences Stock Performance

TLSI stock opened at $5.38 on Friday. The firm’s fifty day moving average is $4.66 and its 200 day moving average is $4.74. TriSalus Life Sciences, Inc. has a one year low of $3.50 and a one year high of $10.42.

Institutional Trading of TriSalus Life Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in TriSalus Life Sciences during the third quarter valued at $92,000. Geode Capital Management LLC grew its position in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares during the period. Vestcor Inc acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at about $108,000. MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at about $184,000. Finally, Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at about $66,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

Analysts Set New Price Targets

TLSI has been the subject of a number of research analyst reports. Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Northland Securities initiated coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target for the company. Roth Mkm reissued a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Buy” and an average price target of $11.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.